Glenmark launches first oral coronavirus drug in India called FabiFlu
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
"This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added.
France pledges funding UK begins coronavirus vaccine trial
Rich countries are scrambling to reserve coronavirus vaccine doses, which probably means poorer countries will have to wait
Johnson & Johnson is moving its coronavirus vaccine into human trials by July, 2 months ahead of schedule
Popular on BI
- Which countries are most affected by severe seismic activity? New earthquake metric provides fresh perspective
- Exicom Tele-Systems to raise ₹429 cr via IPO; sets price band at ₹135-142/share
- Kawasaki Ninja 500 sports bike launched in India at ₹5.24 lakh
- Vodafone Idea board to meet on Feb 27 to consider fundraising proposal
- Stocks rebound: Sensex jumps over 500 points, Nifty hits fresh high